Theravance Announces Positive Phase 2 Clinical Results In The MABA Respiratory Program For The Treatment Of COPD

Theravance, Inc. (NASDAQ: THRX) announced the positive results from a Phase 2 study of the lead investigational compound GSK961081 (’081) in the inhaled bifunctional muscarinic antagonist-beta2 agonist (MABA) program. The MABA program was licensed to GlaxoSmithKline (GSK) in 2005 under the terms of the companies’ Strategic Alliance Agreement as a potential treatment for patients with chronic obstructive pulmonary disease (COPD).

More: continued here

Filed under: Clinical Trials on July 16th, 2008